Squarex unveils Phase 2 results of SQX770 in recurrent herpes labialis
Category: #health  By Mateen Dalal  Date: 2019-08-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Squarex unveils Phase 2 results of SQX770 in recurrent herpes labialis

The study involved around 139 subjects who had reported four or more episodes of herpes labialis in the past 12 months

Squarex, a clinical-stage pharmaceutical company has reportedly unveiled the positive results from a Phase 2 clinical trial of its investigational compound, SQX770, which is a tropical formulation of the immunomodulator squaric acid dibutyl ester, in patients with oral herpes.

Apparently, the company aims to initiate a Phase 3 study after a planned FDA end of Phase 2 clinical meeting later in the year.

Sources close to the matter informed that the placebo-controlled, multi-center, double-blinded randomized Phase 2 study involved around 139 subjects who had reported four or more episodes of herpes labialis in the past 12 months. The study was formally designed to ascertain if the topical application of SADBE is able to delay HSV-1 outbreaks.

Seemingly, results from the Phase 2 clinical trial defined that a single topical dosage of SQX770 applied to the upper arm substantially extended time to subsequent herpes labialis outbreak and reduced both the severity and frequency of outbreaks. The greatest effect was registered during days 43 to 121 following the application of drug. These findings indicate SQX770 immunotherapy can take up to 6 weeks to completely exert a clinically significant effect on the immune system.

Sources further stated that no serious adverse events were reported so far. The adverse events that were officially reported, like local reaction owing to the sensitization and challenge responses on the skin, were what investigators anticipated to witness using a topical immunomodulator.

According to Jack Talley, Chief Executive Officer of Squarex, the company’s findings confirm and validate the results from two former studies including a prior placebo controlled clinical trial and therefore, open the way for the initiation of a Phase 3 clinical trial. With no existing preventative treatment options available on the market for the millions of patients who are suffering from recurrent HSV-1 outbreaks, Squarex is ready to continue the clinical development and could expectedly bring the first and only option for combating herpes labialis.

Source Credits: https://www.prnewswire.com/news-releases/squarex-announces-positive-results-from-completed-phase-2-study-of-sqx770-in-the-prevention-of-recurrent-herpes-labialis-300896065.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Alphabet’s Google to face lawsuit from NLRB for violating labor laws
Alphabet’s Google to face lawsuit from NLRB for violating labor laws
By Mateen Dalal

In a recent turn of events, U.S. government body National Labor Relations Board (NLRB) has reportedly issued a complaint against American multinational technology company, Google LLC for unlawfully monitoring as well as questioning its workers and su...

Britain’s CMA to levy tougher competition rules on Google and Facebook
Britain’s CMA to levy tougher competition rules on Google and Facebook
By Mateen Dalal

Facebook and Google accounted for around 80% of the total 14 billion pounds spent on digital advertising in 2019. MOW has reportedly accused Google of modifying its Chromium developer tools and Chrome browser to get greater control over advertiser...

Amazon, U.S. Government team up to prevent sale of counterfeit goods
Amazon, U.S. Government team up to prevent sale of counterfeit goods
By Mateen Dalal

According to reliable sources, Washington-headquartered American multinational technology company, Amazon.com Inc has reportedly initiated a joint venture with the U.S. government’s counterfeit agency, the IPR Center (National Intellectual Prop...